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Background: Vitamin K2 contributes to bone and cardiovascular health. Therefore, two vitamin K2 homologues,
menaquinone-4 (MK-4) and menaquinone-7 (MK-7), have been used as nutrients by the food industry and as
nutritional supplements to support bone and cardiovascular health. However, little is known about the
bioavailability of nutritional MK-4. To investigate MK-4 and MK-7 bioavailability, nutritional doses were administered
to healthy Japanese women.
Findings: Single dose administration of MK-4 (420 μg; 945 nmol) or MK-7 (420 μg; 647 nmol) was given in the
morning together with standardized breakfast. MK-7 was well absorbed and reached maximal serum level at 6 h
after intake and was detected up to 48 h after intake. MK-4 was not detectable in the serum of all subjects at any
time point. Consecutive administration of MK-4 (60 μg; 135 nmol) or MK-7 (60 μg; 92 nmol) for 7 days
demonstrated that MK-4 supplementation did not increase serum MK-4 levels. However, consecutive administration
of MK-7 increased serum MK-7 levels significantly in all subjects.
Conclusions: We conclude that MK-4 present in food does not contribute to the vitamin K status as measured by
serum vitamin K levels. MK-7, however significantly increases serum MK-7 levels and therefore may be of particular
importance for extrahepatic tissues.
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Vitamin K acts as a cofactor for the endoplasmic enzyme
γ- glutamylcarboxylase during the post-translational
conversion of glutamic acid residues of specific proteins
to γ-carboxyglutamic acid (Gla) to form Gla-containing
proteins. A number of blood coagulation factors including
coagulation factors II (prothrombin), VII, IX, and X are
well-known examples of Gla-containing proteins, which
are synthesized in the liver. Osteocalcin, a bone-specific
protein synthesized by osteoblasts, and matrix Gla protein
synthesized in blood vessel and bone are Gla-containing
proteins synthesized at extra-hepatic sites [1].
There are two naturally occurring forms of vitamin K:
vitamin K1 (phylloquinone) derived from green plants
and vitamin K2 (menaquinones, MK-n), which is a series
of vitamers with multi-isoprene units at position 3 of the
common 2-methyl-1,4-naphthoquinone ring structure.* Correspondence: toshiro.sato@j-oil.com
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reproduction in any medium, provided the orIn food, vitamin K1 is bound to the chloroplast mem-
brane of leafy green vegetables. MK-4 is found in animal
products such as eggs, meat, and liver. MK-4 is derived
from the conversion of menadione (synthetic analog of
vitamin K only consisting of the 2-methyl-1,4-naphtho-
quinone ring structure), which is given to the animals.
Long chain menaquinones (i.e. MK-7, MK-8, and MK-9)
are found in fermented foods such as cheese, curd, and
sauerkraut [2]. The Japanese fermented food “natto” con-
tains MK-7 at an exceptionally high concentration [2].
The effects of long chain MK-n such as MK-7 on normal
blood coagulation is greater and longer lasting than vita-
min K1 and MK-4 [3-5]. The effect of natto derived MK-7
was attributed to its very long half-life in serum, providing
a better carboxylation-grade of osteocalcin compared to
Vitamin K1 [5].
Recent studies revealed that vitamin K2 contributes to
both bone and cardiovascular health [6-8]. Both MK-4
and MK-7 have been used as nutritional ingredients. It
has been shown that all vitamin K homologues can be
converted to MK-4 in vivo [9-11]. MK-4 is thought tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and




























Figure 1 Change in serum vitamin K2 levels following a single
oral dose (420 μg) of MK-4 or MK-7. Each point represents the
mean ± SEM of 5 subjects at 0, 2, 4, 6, 10, 24, 48 and 72 h. ■=MK-4;
○=MK-7.
Sato et al. Nutrition Journal 2012, 11:93 Page 2 of 4
http://www.nutritionj.com/content/11/1/93have specific functions other than γ-carboxylation of
vitamin K-dependent proteins [12,13]. However, only lit-
tle is known about the bioavailability of the nutritional
dose of MK-4 [7]. In this study, we compared the bio-
availability of MK-4 and MK-7 and subsequent changes
in serum levels in healthy volunteers.
Methods
Subjects
Ten healthy female volunteers (age: 20–21 years, mean
BMI: 20.4 kg/m2) not currently taking any medication
were selected from the student population of the La-
boratory of Physiological Nutrition at Kagawa Nutrition
University. Subjects were not allowed to take natto and
vitamin supplements other than the experimental ver-
sions provided during the study. Approval for both stud-
ies was obtained from the Ethics Committee of Kagawa
Nutrition University. Informed consent of all volunteers
was provided in accordance with the Declaration of
Helsinki.
Study 1
Ten healthy female subjects (age: 20–21 years) were ran-
domized into two groups (n = 5). A single dose of MK-4
(420 μg; 945 nmol) or MK-7 (420 μg; 647 nmol) was
administered to each subject within 10 min after ingest-
ing a breakfast containing 13–17 g of fat. All subjects
received the same meals, and the nutrients and energy
levels were adjusted according to the Japanese Dietary
Reference Intake and National Health and Nutrition
Examination Survey. The amount of 420 μg is equivalent
to the MK-7 concentration in natto and is 7 times higher
than the recommended dietary intake (RDI) of vitamin
K for Japanese women (age: 19–29 years). Blood (2 ml)
was taken to prepare serum before the administration of
vitamin K at baseline (t=0), and at 2, 4, 6, 8, 10, 24, 48,
and 72 h after administration. Serum MK-4 and MK-7
levels were determined by HPLC analysis as described
below.
Study 2
Ten healthy female subjects (age: 20–21 years) were ran-
domized into two groups (n = 5). MK-4 (60 μg; 135 nmol)
or MK-7 (60 μg; 92 nmol), equivalent to the RDI, was
administered daily after supper for one week. Subse-
quently, serum MK-4 and MK-7 levels were determined.
Materials
MK-4 and MK-7 for the analytical standard were gifted
by Eisai (Tokyo, Japan) and Hofmann-La Roche (Basel,
Switzerland), respectively. Pure MK-4 (98.5%) and MK-7
(98.7%) used for the human study were prepared by J-Oil
Mills (Fukuroi, Japan) with purity determined by HPLC
[4]. Preparation consisted of dilution into hydrogenatedstarch hydrolyze powder, which was packed in gelatin
capsules. The capsules were then packed in an aluminum-
light-shed bag and kept in a refrigerator until use. After
study completion, we re-analyzed and confirmed that
neither MK-4 nor MK-7 decreased during storage (data
not shown).
Measurements of serum vitamin K2
Serum vitamin K was measured using HPLC with fluor-
escence detection after on-line, post column zinc reduc-
tion, which converts quinone forms of vitamin K into
their fluorescent quinol forms, as described previously
[5]. Samples were extracted using hexane. Vitamin K1-25
(GLSynthesis Inc., Worcester, MA) was used as internal
standard. The detection limit of MK-4 and MK-7 were
16 pg/ml and 40 pg/ml, respectively. Results were
expressed as the mean ± standard error (SEM).
Results
Study 1
Serum vitamin K2 levels were compared after a single oral
administration (420 μg) of MK-4 or MK-7 in healthy Japa-
nese females. Baseline serum levels of MK-4 and MK-7
were not detected. Single intake of MK-7 increased serum
MK-7 in all subjects, which reached maximum levels at
6 h after administration. MK-7 was detected 48 h after
administration (Figure 1). On the contrary, serum MK-4
was not detected at any time point (Figure 1).
Study 2
Serum vitamin K2 levels were compared after consecu-
tive administration of MK-4 and MK-7 (60 μg/day) for
7 days. Baseline serum level of MK-4 was 2.2 ng/ml ± 0.38
and that of MK-7 was less than detection limit. After
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Figure 2 Increased serum vitamin K2 levels in subjects after
7 days of consecutive administration (60 μg/day). Each value is
expressed as the mean ± SEM of 5 subjects. ■=MK-4;□=MK-7.
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0.27 in the MK-4 and MK-7-treated groups, respectively.
While MK-4 intake did not increase MK-4 administered
group, serum MK-7 increased significantly in MK-7-
administered-subjects (Figure 2).
Discussion
The current study shows that MK-4 has a poor bioavail-
ability at a nutritional level dose, whereas MK-7 is well
absorbed and detectable in the blood at nutritional levels.
In a study from the Netherlands, they compared the
absorption of 900 μg of vitamin K1, MK-4, and MK-9.
MK-4 showed a short serum half-life and small area
under the curve compared to vitamin K1, whereas MK-9
displayed a long serum half-life compared to vitamin K1
or MK-4 [14]. Takeuchi et al. [15] reported a dose finding
study of MK-4 to increase osteocalcin carboxylation
in healthy subjects. In their study, supplementation of
500 μg MK-4/day for 2 months showed no effects on
carboxylation of osteocalcin, whereas a dose of 1500 μg
MK-4/day was required to improve carboxylation of
osteocalcin. From these and our data we can conclude
that MK-4 intake of greater than 420–500 μg is
required.
Consecutive MK-4 supplementation did not increase
plasma MK-4 levels whereas MK-7 supplementation
significantly increased plasma MK-7 levels in healthy
female subjects. This is in-line with previous pub-
lished works, which indicated nutritional doses of
MK-7 (45–90 μg/day) to be effective for carboxylation
of osteocalcin [16,17].
Because all vitamin K homologues can be converted to
MK-4 in vivo, MK-4 is considered to have specific func-
tions other than γ-carboxylation of vitamin K-dependent
proteins [9-11]. However, in a previous rat study fromour group [18], the intake of a nutritional dose of MK-4
did not increase the MK-4 levels in extrahepatic tissues,
whereas MK-7 significantly increased MK-4 in extrahe-
patic tissues. Thus, MK-7 is a better supplier for MK-4
in vivo than MK-4 itself.
In this study, we demonstrated that a nutritional dose
of MK-7 is well absorbed in human, and significantly
increases serum MK-7 levels, whereas MK-4 had no
effect on serum MK-4 levels. Therefore, the nutritional
values of vitamin K2 homologues should be differen-
tiated with regard to bioavailability and efficacy.
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